Figure 6.

Therapeutic advancements achieved during a progressive molecular age for MAPK-driven hematopoietic neoplasms. (A) Timeline documenting the targeted therapeutic achievements in the histiocytic neoplasms and hairy cell leukemia over the past decade. (B) Diagram summarizing the molecular targeted therapies that have or may demonstrate clinical efficacy in the histiocytic neoplasms. (C) Diagram of a composite therapeutic algorithm for the first-line, second-line, and relapsed/refractory treatment of classical hairy cell leukemia based on current advancements during the molecular age. (D) Diagram of a composite therapeutic algorithm for the first-line and relapsed/refractory treatment of hairy cell leukemia variant founded on current molecular progress. SH, Systemic histiocytoses; ECD, Erdheim–Chester disease; cHCL, classical hairy cell leukemia; vHCL, hairy cell leukemia variant; FDA, Food and Drug Administration; PNA, purine analog; IFN, interferon; BTK, Bruton tyrosine kinase; CR, complete response.